中国综合临床
中國綜閤臨床
중국종합림상
CLINICAL MEDICINE OF CHINA
2014年
9期
957-960
,共4页
徐学新%蒙艳凤%杨国稳%张文军%刘亚静%唐立环%张炜%魏朝辉
徐學新%矇豔鳳%楊國穩%張文軍%劉亞靜%唐立環%張煒%魏朝輝
서학신%몽염봉%양국은%장문군%류아정%당립배%장위%위조휘
卵巢癌%腹腔热灌注%奈达铂%草酸铂%化疗效果
卵巢癌%腹腔熱灌註%奈達鉑%草痠鉑%化療效果
란소암%복강열관주%내체박%초산박%화료효과
Ovarian cancer%Hyperthermic peritoneal perfusion%Nedaplatin%Oxaliplatin%Chemotherapy effect
目的 观察奈达铂和草酸铂在腹腔热灌注治疗卵巢癌的效果和不良反应.方法 选取卵巢癌合并腹腔积液和术后及术后复发的患者57例,随机分为观察组32例和对照组25例.分别应用奈达铂和草酸铂热灌注治疗,即将奈达铂或草酸铂用体腔热灌注机加热到42～ 43℃,以一定速度灌注入腹腔.观察灌注治疗后的效果和不良反应.结果 两组近期效果比较:全部病例随访6个月以上,观察组腹水控制率为90.6％,其中CR 34.4％ (11/32),PR 56.2％ (18/32);对照组腹水控制率为68.0％,其中CR 16.0％ (4/25),PR 52.0％(13/25),观察组与对照组比较差异有统计学意义(x2=39.36,P＜0.05).观察组严重不良反应轻于对照组.结论 奈达铂用于腹腔热灌注治疗卵巢癌较草酸铂具有效果好,不良反应少的优点,可提高患者化疗的依从性和完成化疗周期.
目的 觀察奈達鉑和草痠鉑在腹腔熱灌註治療卵巢癌的效果和不良反應.方法 選取卵巢癌閤併腹腔積液和術後及術後複髮的患者57例,隨機分為觀察組32例和對照組25例.分彆應用奈達鉑和草痠鉑熱灌註治療,即將奈達鉑或草痠鉑用體腔熱灌註機加熱到42～ 43℃,以一定速度灌註入腹腔.觀察灌註治療後的效果和不良反應.結果 兩組近期效果比較:全部病例隨訪6箇月以上,觀察組腹水控製率為90.6％,其中CR 34.4％ (11/32),PR 56.2％ (18/32);對照組腹水控製率為68.0％,其中CR 16.0％ (4/25),PR 52.0％(13/25),觀察組與對照組比較差異有統計學意義(x2=39.36,P＜0.05).觀察組嚴重不良反應輕于對照組.結論 奈達鉑用于腹腔熱灌註治療卵巢癌較草痠鉑具有效果好,不良反應少的優點,可提高患者化療的依從性和完成化療週期.
목적 관찰내체박화초산박재복강열관주치료란소암적효과화불량반응.방법 선취란소암합병복강적액화술후급술후복발적환자57례,수궤분위관찰조32례화대조조25례.분별응용내체박화초산박열관주치료,즉장내체박혹초산박용체강열관주궤가열도42～ 43℃,이일정속도관주입복강.관찰관주치료후적효과화불량반응.결과 량조근기효과비교:전부병례수방6개월이상,관찰조복수공제솔위90.6％,기중CR 34.4％ (11/32),PR 56.2％ (18/32);대조조복수공제솔위68.0％,기중CR 16.0％ (4/25),PR 52.0％(13/25),관찰조여대조조비교차이유통계학의의(x2=39.36,P＜0.05).관찰조엄중불량반응경우대조조.결론 내체박용우복강열관주치료란소암교초산박구유효과호,불량반응소적우점,가제고환자화료적의종성화완성화료주기.
Objective To investigate the effect of Nedaplatin and oxaliplatin in hyperthermic peritoneal perfusion treatment of patients with malignant ascites as well as its adverse chemotherapy effect.Methods Fifty seven ovarian cancer patients of with ascites were randomly divided into the observation group(32 cases) and the control group (25 cases).Patients were respectively treated with nedaplatin or oxaliplatin for intraperitoneal hyperthermic perfusion.The nedaplatin plus saline 2 000 ml or oxaliplatin plus 5％ glucose 2 000 ml were heated with hyperthermic perfusion machine to 42-43℃,and then infusion into abdominal cavity of patients at certain speed.The efficiency and toxicity of the two groups after reperfusion were recorded.Results All patients were followed up for 6 months.The control rate of ascetic fluid in observation group was 90.6％,of which,CR was 34.4％ (11/32) and PR 56.2％ (18/32).The control rate of ascetic fluid in control group was 68.0％,of which,CR was16.0％ (4/25) and PR was 52.0％ (13/25).The difference between observation and control group was statistically significant in terms of therapy efficacy(x2 =39.36,P ＜0.05).The side effect in patients of observation group was slight than that in control group.Conclusion Nedaplatin for intraperitoneal hyperthermic perfusion with oxaliplatin has advantages with good curative effect,low toxicity,which can improve the compliance of chemotherapy in order to complete chemotherapy cycles.
